Tag Archives: heart failure
man holding chest and woman offering him water

To Supplement or Not: A Role for Antioxidant Vitamins in the Management of Heart Failure?

  There is an epidemic of heart failure occurring in advanced industrial nations. The number one diagnosis for payment by Medicare in the US is heart failure. Because heart failure is increasingly prevalent among the elderly, and because the population of individuals older than age 65 years is increasing rapidly in the US, patients with […]

Read more
Pathophysiologic factors leading to alterations in levels of biomarkers used in the assessment and management heart failure. Note procalcitonin is not actually released from the heart, while NPs, ST2, and high-sensitivity troponin are released from the heart. NP = natriuretic peptide; NEP = neutral endopeptidase; hs = high-sensitivity.

Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine

Abstract Biomarkers have become an integral part of practicing medicine, especially in heart failure. The natriuretic peptides are commonly used in the evaluation of heart failure, but their role extends beyond diagnosis and includes risk stratification and management of heart failure patients. Newer biomarkers have arrived and are becoming part of routine care of heart […]

Read more
Dr. Joseph S. Alpert

Heart Failure with Preserved Ejection Fraction (video)

Heart failure is usually broken down into two categories: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Hospitalizations for both are comparable, but HFpEF hospitalizations are expected to increase in the future. Consequently, there is a need for better treatments for HFpEF patients. In this video, AJM Editor-in-chief […]

Read more
heart-dis-stock

Contemporary Role for Digoxin in Heart Failure

Physicians who see patients with heart failure (HF) with reduced ejection fraction (HFrEF) must deal with these patients’ symptoms of exercise intolerance, fatigue, and congestion that often lead to hospitalization, despite correct application of guideline-recommended life-prolonging therapies. The result is the current cost of $30 billion spent annually for HF hospitalizations alone, and given the […]

Read more
UA-42320404-1